AlphAIAlphAI — Financial news for AI agents
tradingview.comAUG 212 min read$CLX

Clorox Stock Jumps 13.1% in a Month. Can the Gains Keep Building?

Clorox (CLX) stock rose 13.1% in a month after beating Q4 earnings and revenue estimates, with adjusted EPS of $1.66 and sales of $1.95B. The company expects fiscal 2027 sales growth of 13-14% and EPS of $5.70-$6.00, driven by GOJO acquisition and ERP benefits. However, margins remain pressured by inflation and softer demand, with gross margin declining to 41.3% in Q4. Organic sales growth is expected to be flat to slightly positive, excluding ERP effects.

Original reporting
tradingview.com
Published Aug 21, 2026, 5:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Clorox Stock Jumps 13.1% in a Month. Can the Gains Keep Building? — source image
Source · tradingview.com
Decision brief

The 30-second read

$CLXBullishLow
01

Why it matters

Earnings beat and guidance provide a short‑term catalyst, but long‑term execution risk remains.

02

Market read

The earnings beat offers modest trading interest; investors should monitor margin trends.

03

What to watch

Potential inventory drawdown effects and inflation‑driven cost headwinds.

Relevance 5/10Novelty 7/10Timing: post‑earnings release

Background

Clorox's Q4 results and FY2027 outlook were released amid a broader consumer‑staples slowdown.

Company-level read

Ticker impact

$CLXBullishMedium confidence
Context

Clorox reported Q4 earnings beat ($1.66 EPS vs $1.64 est) and issued FY2027 guidance of $5.70‑$6.00 EPS, prompting a 13.1% price gain.

Expected impact

Potential continuation of rally, but risk if margins stay weak.

Evidence & confidence

Guidance relies heavily on acquisition and ERP effects; margin pressure remains a downside.

Market effects

Sector

Consumer staples peers may face similar margin pressure, limiting relative outperformance.

Regional

U.S. consumer discretionary market sees modest uplift from earnings beat.

Global

Limited; primarily affects U.S. consumer‑staples investors.

Counterpoint

What could challenge this read

Margin compression and reliance on acquisition growth could stall the rally.

Key entities

  • Company
    Clorox Company

    Consumer‑staples firm reporting earnings and guidance.

  • Acquired Company
    GOJO Industries

    Acquisition contributing to sales growth.

Read at source← All news

Related articles

SEP 17
$CLXMedAI 8/10

Clorox stock hits 52-week low at 84.69 USD

Clorox (CLX) stock hit a 52-week low of $84.74, down 31.51% over the past year. Despite this, InvestingPro suggests it's undervalued with a 5.89% dividend yield. Q4 earnings per share were $1.66, missing estimates. UBS raised its price target to $105, maintaining a Neutral rating. Goldman Sachs and Morgan Stanley reported on broader consumer staples trends.

investing.com2 min
SEP 3
$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

finance.yahoo.com2 min
AUG 21
$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

tradingview.com3 min
AUG 21
$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

tradingview.com3 min
AUG 14
$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

yahoo.com6 min
AUG 11
$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

fool.com6 min